Early re-entry does the trick

Posted 23 August 2021 AM

Four out of five PBAC submissions that used the early re-entry pathway won a positive recommendation and the fifth has been deferred - results that suggest the new system could be working. 

Outcomes from the July meeting included positive recommendations for Bayer's Nubeqa for castration resistant carcinoma of the prostate, Otsuka's Inqovi for high risk myelodysplastic syndromes and chronic myelomonocytic leukaemia, STA's Qinlock for gastrointestinal stromal tumour and AbbVie's Venclexta for acute myeloid leukaemia.

To see the whole article, please login